Medtronic Stock Surges After Q1 Earnings Beat and Raised Guidance

Medtronic (NYSE: MDT) stock surged 4.8% in pre-market trading to $95 after the medical device company announced fiscal first-quarter 2027 results that surpassed analyst expectations and raised its full-year guidance. The positive report stood in contrast to the broader market, with major U.S. indices trading lower before the opening bell.

Earnings Beat and Upgraded Outlook

Medtronic reported strong top- and bottom-line performance for the quarter, signaling robust business momentum. The company also lifted its financial forecast for the full fiscal year 2027, indicating management's confidence in sustained growth.

Key figures from the report include:

• Q1 Revenue: $9.8 billion, representing a 13.7% organic increase, which was approximately 200 basis points above the company's own guidance.
• Q1 Non-GAAP EPS: $1.45, comfortably ahead of the Wall Street consensus of $1.39.
• FY27 Organic Revenue Growth Guidance: Raised by 50 basis points to a new range of 7.25% to 7.75%.
• FY27 Non-GAAP EPS Guidance: Lifted to a range of $5.94 to $6.00.

Cardiovascular Segment Powers Growth

Ad

The earnings beat was broad-based, but performance in the Cardiovascular segment was particularly noteworthy, growing 18.9% year-over-year. This was driven by a 15% increase in Cardiac Rhythm Management and a remarkable 88% surge in its Cardiac Ablation Solutions business.

Adding to the positive news, Medtronic also announced it received an expanded CE Mark indication in Europe for its Affera Mapping and Ablation System. This regulatory milestone helps reinforce the company's competitive standing in the electrophysiology market.

Market Context

The stock's significant pre-market rally came as the S&P 500, Dow Jones, and Nasdaq all pointed to a lower open, underscoring that the move was driven by company-specific catalysts rather than general market sentiment. The results appeared to validate optimistic analyst forecasts, including a recent price target increase from Needham to $114 and a broader Wall Street consensus price target of $98.84.